Oct. 20, 2014 — InfraScan, a medical device firm specializing in brain injury diagnostic products, signs a $3.7 million, 4-year contract with the U.S. Marine Corps and the Navy. The project provides for advanced technology development and field evaluation activities to develop a next-generation version of the company's Infrascanner brain hematoma detector.
The Infrascanner is a commercially available, non-invasive device, which can detect the presence of a brain hematoma based on differential NIR light absorption of a hematoma and normal brain tissue.
The military contract will support the development of new, integrated capabilities including the ability to: detect changes in local oxygen saturation within brain and extremity tissues; detect brain edema and administer a neurological concussion evaluation exam. The device will support expedient assessment and triage of brain injured personnel.
InfraScan will partner with researchers in Drexel University's School of Biomedical Engineering, Science and Health Systems will redesign the device and test the new prototype. Drexel biomedical engineers participated in the design and testing of the original Infrascanner and will utilize their expertise in the optical brain imaging technology they've been developing.
The Infrascanner has been awarded the CE mark, Canada Health and FDA clearance.
For information: www.infrascanner.com
February 16, 2026 
